NAD+ (NAD)

Pen Peptide manufacturer protocol depends on pen variant:

• 1200mg pen (1 click = 4 mg): 10 clicks × 2 times/day every other day — 1 pen fully covers 30-day course. This is the main recommendation.

• 500mg pen (1 click ≈ 1.66 mg): 24 clicks × 2 times/day every other day — for those wanting to start with smaller variant.

• 200mg pen (1 click = 1 mg): for starter 10-day course 20 clicks × 2 times/day; or for 30-day — 7 clicks/day with daily administration.

Subcutaneous injection in abdomen or anterior thigh. Rotate injection sites. Better in morning or before 4 PM (excess energy may interfere with sleep).

Every other day is fundamental: NAD+ has cumulative effect, rest days allow cells to "assimilate" the coenzyme.

Break between courses 15–20 days. Optimal 2–3 courses per year.

Storage: NAD+ is sensitive to LOW temperatures — DO NOT freeze. Store at 2–8°C or room temperature (manufacturer allows), avoid direct sunlight.

Before starting — DOZA specialist consultation and glucose analysis (NAD+ affects its metabolism).

NAD+ (nicotinamide adenine dinucleotide) is a critically important coenzyme involved in over 500 enzymatic reactions in every cell of the body. It regulates cellular energy (electron transfer in mitochondria), glucose and lipid metabolism, DNA repair, sirtuin activity (longevity proteins), and circadian rhythm. NAD+ levels naturally decline by half every 20 years after age 30, which is associated with most age-related changes: energy loss, memory decline, slowed metabolism and regeneration.

Pen Peptide produces NAD+ in pre-mixed pen format in three sizes (200mg/500mg/1200mg), purity ≥98%, GMP-standard + stabilized MSSPT-formula. Manufacturer protocol for 1200mg pen — 10 clicks × 2 times daily every other day, 30 days — 1 pen fully covers the course. The advantage of subcutaneous NAD+ is bypassing hepatic metabolism and direct delivery of cofactor to tissues, unlike oral NMN/NR precursors that require conversion.

In clinical studies, NAD+ has shown efficacy in normalizing metabolism in diabetic patients, improving cognitive function in mild cognitive impairment, activating mitochondrial biogenesis, antioxidant DNA protection, potential in Parkinson's and Alzheimer's disease. In the context of GLP-1 weight loss programs, NAD+ compensates for possible energy reduction and supports thermogenesis.

NAD+ (nicotinamide adenine dinucleotide) is a universal coenzyme of electron transport in mitochondria, participating in over 500 enzymatic reactions in every cell of the organism.

Main mechanism: NAD+ is a key substrate for sirtuins (SIRT1-SIRT7) — longevity proteins that deacetylate histones and regulate gene expression of mitochondrial biogenesis, cellular stress, and metabolism. SIRT1 activation improves insulin sensitivity, accelerates fatty acid oxidation, and supports thermogenesis in brown adipose tissue.

Concurrently, NAD+ serves as substrate for PARP-1 enzyme, responsible for DNA repair — protection from mutations and premature aging. It's also involved in CD38 signaling (immune function) and Krebs cycle (main source of cellular energy ATP).

Critical difference of subcutaneous NAD+ from oral NMN/NR precursors: injection bypasses gastrointestinal-hepatic metabolism and delivers ready coenzyme directly to muscles, brain, and skin. NMN first undergoes conversion through NMNAT enzyme — only part of the dose reaches cells as NAD+.

NAD+ levels decline by half every 20 years after age 30 (Camacho-Pereira et al., Cell Metabolism 2016). This correlates with energy loss, metabolism slowdown, cognitive function decline, and accelerated aging. Exogenous administration restores mitochondrial efficiency and sirtuin activity.